Nextcure presents biomarker data and updated clinical results from phase 1 portion of its nc318 clinical trial

Nextcure presents biomarker data and updated clinical results from phase 1 portion of its nc318 clinical trial at the 2020 virtual american society of clinical oncology annual meeting.nextcure inc - early biomarker data suggest collectively potential of nc318 to block s15-mediated immune suppression.nextcure inc - early biomarker data suggest increase of pd-1 expression on circulating cd4+ t cells while on treatment.
NXTC Ratings Summary
NXTC Quant Ranking